By Katherine Hamilton
PMGC said its subsidiary amended a drug license agreement to expedite the clinical trial process. Shares gained 78% to $2.99 in after-hours trading Friday.
Cue Biopharma said its chief executive is resigning and will be replaced in the interim by its chief financial and business officer. The stock fell 4% to 23 cents after the bell.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
March 27, 2026 18:39 ET (22:39 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.